Journal
SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA
Volume 22, Issue 3, Pages 306-323Publisher
SAGE PUBLICATIONS INC
DOI: 10.1177/1089253217749298
Keywords
prostacyclin; prostaglandins; pulmonary hypertension; prostaglandins in cardiac surgery; right heart failure; heparin-induced thrombocytopenia; cardiac surgery
Categories
Ask authors/readers for more resources
Prostacyclin (prostaglandin I-2 [PGI(2)]) is an eicosanoid lipid mediator produced by the endothelial cells. It plays pivotal roles in vascular homeostasis by virtue of its potent vasodilatory and antithrombotic effects. Stable pharmacological analogues of PGI(2) are used for treatment of pulmonary hypertension and right ventricular failure. PGI(2) dose dependently inhibits platelet activation induced by adenosine-5-diphosphate, arachidonic acid, collagen, and low-dose thrombin. This property has led to its use as an alternative to direct thrombin inhibitors in patients with type II heparin-induced thrombocytopenia (HIT) undergoing cardiac surgery. The aims of this review are the following: (1) to review the pharmacology of PGI(2) and its derivatives, (2) to present the evidence for their use in pulmonary hypertension and right heart failure, and (3) to discuss their utility in the management of HIT in cardiac surgery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available